How Novo Nordisk A/S (ADR) (NVO) Will Deal With A Diabetes Delay: Sanofi SA (ADR) (SNY), Johnson & Johnson (JNJ)

Page 1 of 2

Novo Nordisk A/S (ADR) (NYSE:NVO) recently got some bad news from the Food and Drug Administration: a request for additional information about a key insulin product. That notice could delay the new treatment’s launch until at least 2015 — a big delay, but one the company can probably handle.

Novo Nordisk A/S (ADR) (NYSE:NVO)Novo Nordisk

Novo Nordisk started treating people with insulin in 1923. Today, insulin is the company’s core market, with a 49% share of the world market based on volume. While the company has other areas on which it focuses, including hemophilia and weight loss (intimately tied to diabetes and insulin), it derives nearly 80% of its revenues from its diabetes business. Insulin, then, is ultra-important to Novo’s long-term success.

This market holds great opportunity, too. For example, the company believes that there are over 370 million people with diabetes in the world today. It expects that number to increase to 550 million by 2030. The United States is one of the leading markets, largely because of an aging and increasingly overweight population, factors that increase the incidence of type 2 diabetes. China, however, is an up-and-coming market for the Novo as well.

Novo Nordisk A/S (ADR) (NYSE:NVO) estimates that there are over 90 million people in China with diabetes, making it the world’s largest diabetes market. Interestingly, the same reasons that have made the United States such an important market are increasingly hurting Chinese citizens. “With economic growth comes urbanisation, with urbanisation come sedentary lifestyles – and then diabetes follows.” Management estimates that 90% of people with diabetes have type 2.

Less Shots

The big pushes in diabetes research are to reduce the number of times that a diabetic has to medicate, and to improve the medication delivery method. Injection is the main method for getting insulin into the body. Clearly, that’s not a desirable approach, so reducing the number of times that a patient has to inject themselves, or completely altering the way in which insulin is delivered, would be a huge benefit and likely lead to a blockbuster drug.

This is where the company’s once-a-day Tresiba comes into play. The drug has been approved in Japan, Mexico, and in the European Union. However, in early 2013, the FDA chose not to approve the drug, asking instead for additional research into Tresiba’s potential cardiovascular risks.

A Big Hit

After receiving approval in the other markets, the FDA’s decision came as something of a shock to the market. At one point following the news, Novo Nordisk’s shares were down as much as 17%. While the shares rebounded from those depths, the announcement sent the shares notably lower.



NVO data by YCharts

Providing the research to the FDA will be expensive and time-consuming. In fact, Reuters reported that Novo’s Chief Scientific Officer, Mads Thomsen, said that the company probably wouldn’t be able to provide the information until after 2014. Some market watchers estimate that even 2015 could be an aggressive expectation. A multi-year delay is clearly not a good thing for the company’s prospects, since the U.S. market is so important to its business.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

10 Top Reasons For Getting Fired

The 3 Best States to Start an LLC

10 Jobs That Allow You to Travel

7 High-Paying Jobs You Can Do From Home

12 Best Cities to Shop in USA

10 Best States To Practice Medicine

The 10 Best States to Have a Business

The 12 Most Expensive Apple (AAPL) Apps in the Market

The 10 Richest Billionaires in the World

10 Biggest Kickstarter Failures

The 10 Best Places to Work At

The Top 10 of Google Inc (GOOGL)’s Most Expensive Acquisitions

13 Best Cities to Visit in South America

10 Most Expensive Works of Art of All Time

The 10 Richest Banks in the World

The 10 Best-Paying Jobs in America (2014)

7 Most Expensive Foods in the World

The World’s Top 10 Earning Authors

Five Wicked and Very Expensive Items (and Other “Stuff”) Sold on eBay

10 Biggest Celebrity Bankruptcies

The Top 10 Highest Paid CEOs in 2014

The 10 Most Expensive Real Estate Cities in America

10 Most Expensive States To Live In America

The 10 Best Airlines in the World

The 10 Best-Selling Cars in 2014

The 10 Best Industries to Invest In

The 10 Most Expensive States to Own a Car In

Top 10 Business Schools in US: 2014 Rankings

Top 20 Female Billionaires in 2014

6 Movies That You Should Watch to Better Understand The Cold War

Top 15 Best Paying Jobs for Women in 2014

Top 6 Things Rich People Do Differently Every Day

5 Retirement Mistakes To Avoid (and Einstein’s Famous Quote)

11 Smartest People in the World

6 Films About the Financial World You Need To Watch (While “The Wolf” is Not Around)

Warren Buffett and Billionaires Are Crazy About These 7 Stocks

The Top 10 States With Fastest Internet Speeds

10 Best Places to Visit in USA in August

Top 10 Cities to Visit Before You Die

Top 10 Genetically Modified Food In the US

15 Highest Grossing Movies Opening Weekend

5 Best Poker Books For Beginners

10 Strategies Hedge Funds Use to Make Huge Returns

Top 10 Fast Food Franchises to Buy

10 Best Places to Visit in Canada

Best Summer Jobs for Teachers

10 Youngest Hedge Fund Billionaires

Top 10 One Hit Wonders of the 90s

Fastest Growing Cities In America

Top 10 U.S. Cities for Freelancers

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!